Despite the knowledge of this genomic landscape, according to current international CLL guidelines, only IGHV and TP53 molecular status are mandatory prior to every treatment decision, being especially relevant the report of TP53 status [10,14,15,16]. This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.